Display options
Cite
Shen Y, Wu SD, Wu L, et al. The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatol Int. 2019;13(5):560-572doi: 10.1007/s12072-019-09952-5.
Shen, Y., Wu, S. D., Wu, L., Wang, S. Q., Chen, Y., Liu, L. L., Li, J., Yang, C. Q., Wang, J. Y., & Jiang, W. (2019). The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatology international, 13(5), 560-572. https://doi.org/10.1007/s12072-019-09952-5
Shen, Yue, et al. "The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis." Hepatology international vol. 13,5 (2019): 560-572. doi: https://doi.org/10.1007/s12072-019-09952-5
Shen Y, Wu SD, Wu L, Wang SQ, Chen Y, Liu LL, Li J, Yang CQ, Wang JY, Jiang W. The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatol Int. 2019 Sep;13(5):560-572. doi: 10.1007/s12072-019-09952-5. Epub 2019 Jul 04. PMID: 31273618.
Copy Download .nbib Format: NLM
Share it on

Hepatol Int. 2019 Sep;13(5):560-572. doi: 10.1007/s12072-019-09952-5. Epub 2019 Jul 04.

The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis.

Hepatology international

Yue Shen, Sheng-Di Wu, Ling Wu, Si-Qi Wang, Yao Chen, Li-Li Liu, Jing Li, Chang-Qing Yang, Ji-Yao Wang, Wei Jiang

Affiliations

  1. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai, People's Republic of China.
  2. Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  3. Department of Gastroenterology, Tongji Hospital, Tongji University, Shanghai, People's Republic of China.
  4. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai, People's Republic of China. [email protected].

PMID: 31273618 DOI: 10.1007/s12072-019-09952-5

Abstract

BACKGROUND AND AIMS: Liver stiffness measurement (LSM) by transient elastography (TE) has been assessed for the evaluation of clinically relevant outcomes in patients with chronic liver diseases (CLDs) while with variable results. This systematic review and meta-analysis aims to investigate the relationship between baseline LSM by TE and the development of clinically relevant outcomes.

METHODS: The systematic review identified eligible cohorts reporting the association between baseline LSM by TE and risk of hepatic carcinoma (HCC), hepatic decompensation (HD), all-cause and/or liver-related mortality and liver-related events (LREs) in CLD patients. Summary relative risks (RRs) with 95% confidence intervals (CIs) were estimated using a random-effect model. The dose-response association was evaluated by generalized least squares trend (Glst) estimation and restricted cubic splines. Commands of GLST, MKSPLINE, MVMETA were applied for statistical analysis.

RESULTS: 62 cohort studies were finally included, reporting on 43,817 participants. For one kPa (kilopascal) increment in baseline liver stiffness (LS), the pooled RR (95% CI) was 1.08 (1.05-1.11) for HCC, 1.08 (1.06-1.11) for all-cause mortality, 1.11 (1.05-1.17) for liver-related mortality, 1.08 (1.06-1.10) for HD and 1.07 (1.04-1.09) for LREs. Furthermore, the nonlinear dose-response analysis indicated that the significant increase in the risk of corresponding clinically relevant outcomes turned to a stable increase or a slight decrease with increasing baseline LS changing primarily in the magnitude of effect rather than the direction.

CONCLUSIONS: The dose-response meta-analysis presents a combination between the levels of baseline LS and RRs for each clinically relevant outcome. TE, which is noninvasive, might be a novel strategy for risk stratification and identification of patients at high risk of developing these outcomes.

Keywords: Cancer; Cirrhosis; Fibroscan; Liver; Outcome

References

  1. JAMA. 2000 Apr 19;283(15):2008-12 - PubMed
  2. N Engl J Med. 2000 Dec 7;343(23):1666-72 - PubMed
  3. Am J Gastroenterol. 2002 Oct;97(10):2614-8 - PubMed
  4. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  5. J Clin Invest. 2005 Feb;115(2):209-18 - PubMed
  6. Hepatology. 2005 Jan;41(1):48-54 - PubMed
  7. Mayo Clin Proc. 2007 Aug;82(8):967-75 - PubMed
  8. J Hepatol. 2008 Apr;48(4):606-13 - PubMed
  9. Hepatology. 2008 Jul;48(1):349-50; author reply 350 - PubMed
  10. Hepatology. 2009 Jun;49(6):1954-61 - PubMed
  11. Hepatology. 2010 Sep;52(3):886-93 - PubMed
  12. Hepatology. 2011 Jan;53(1):325-35 - PubMed
  13. J Hepatol. 2012 Mar;56(3):696-703 - PubMed
  14. Am J Epidemiol. 2012 Jan 1;175(1):66-73 - PubMed
  15. J Viral Hepat. 2012 Feb;19(2):e184-93 - PubMed
  16. Ann Hepatol. 2012 May-Jun;11(3):284-93 - PubMed
  17. AIDS. 2013 Apr 24;27(7):1129-34 - PubMed
  18. Ann Intern Med. 2013 Feb 19;158(4):280-6 - PubMed
  19. Clin Gastroenterol Hepatol. 2013 Dec;11(12):1573-84.e1-2; quiz e88-9 - PubMed
  20. J Hepatol. 2014 Feb;60(2):339-45 - PubMed
  21. Hepatology. 2014 Jul;60(1):65-76 - PubMed
  22. Lancet. 1986 Mar 8;1(8480):523-5 - PubMed
  23. Hepatol Commun. 2018 Feb 13;2(4):467-476 - PubMed
  24. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  25. Biometrics. 1994 Dec;50(4):1088-101 - PubMed
  26. Hepatology. 1995 Jan;21(1):77-82 - PubMed
  27. Epidemiology. 1993 May;4(3):218-28 - PubMed
  28. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed

MeSH terms

Publication Types